Skip to main content
. Author manuscript; available in PMC: 2018 Jul 1.
Published in final edited form as: BJU Int. 2016 Oct 2;120(1):32–39. doi: 10.1111/bju.13651

Table 2.

Percent of participants who use each variable or test for selection and/or monitoring during active surveillance (n = 23).

# (%) Using for selection # (%) Using for monitoring
Age 13 (56.5) 11 (47.8)
PSA or PSA derivative 21 (91.3) 22 (95.7)
Clinical stage 21 (91.3) 19 (82.6)
Grade 23 (100) 21 (91.3)
Other biopsy features 19 (82.6) 15 (65.2)
Imaging 14 (60.9) 12 (52.2)
Other test 8 (34.8) 4 (17.4)